Literature DB >> 15334681

Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity.

Hong-Mei Jiao1, Peng-Yan Xie.   

Abstract

AIM: To examine the effects of tegaserod, a serotonin (5-HT) 4 receptor partial agonist, on abdominal withdrawal reflex (AWR) to rectal distention (RD) and c-Fos expression in limbic system.
METHODS: Neonatal Sprague-Dawley rats randomly received colonic irritation by acetic acid from postnatal day 8 to d 21 as a visceral hypersensitive model (group H) or by intrarectal saline as a control group (group C). When they became adults, rectal distention (RD) was performed by a balloon (6F; Fogarty arterial embolectomy catheter; length, 20 mm; diameter, 2 mm) which was rapidly inflated with increasing volumes of saline (0.4, 0.8 and 1.2 mL) for 20 s at five-minute intervals. Five subgroups of group H (H-saline, H-vehicle, H-Teg0.1, H-Teg0.3 and H-Teg1.0) were injected randomly with saline, vehicle (1-methyl-2-thpyrrolidone) or tegaserod at doses of 0.1, 0.3 and 1.0 mg/kg ip, respectively. Two subgroups of group C (C-Saline and C-Teg1.0) were injected with saline or tegaserod (1.0 mg/kg) ip. RD was performed 10 min after injection, AWR was recorded and c-Fos expression in limbic system was analyzed quantitatively by immunohistochemistry.
RESULTS: Compared to saline, tegaserod significantly inhibited AWR in group H (0.4 mL: from 2.0 to 0.5; 0.8 mL: from 3.5 to 1.5; 1.2 mL: from 4.0 to 3.0, P<0.01), but had no significant effect on group C. Tegaserod dose-dependently attenuated the number of c-Fos positive neurons in limbic structures, anterior cingulate cortex (ACC) showed the greatest attenuation. In group H, tegaserod (1.0 mg/kg) resulted in a significant overall decrease to 57% of H-saline (283+/-41 vs 162+/-16, P<0.01), in ACC to 42% of H-saline (72+/-10 vs 31+/-8, P<0.01). In group C, tegaserod (1.0 mg/kg) resulted in an overall decrease to 77% of C-saline (214+/-13 vs 164+/-22, P<0.01), in ACC to 65% of C-saline (48+/-8 vs 31+/-7, P<0.01).
CONCLUSION: Tegaserod inhibits the response to rectal distention in rats with visceral hypersensitivity and dose-dependently attenuates c-Fos expression in limbic system, especially in anterior cingulate cortex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334681      PMCID: PMC4572113          DOI: 10.3748/wjg.v10.i19.2836

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Induction and adaptation of Fos expression in the rat brain by two types of acute restraint stress.

Authors:  G M Chowdhury; T Fujioka; S Nakamura
Journal:  Brain Res Bull       Date:  2000-06       Impact factor: 4.077

2.  Altered nociceptive neuronal circuits after neonatal peripheral inflammation.

Authors:  M A Ruda; Q D Ling; A G Hohmann; Y B Peng; T Tachibana
Journal:  Science       Date:  2000-07-28       Impact factor: 47.728

3.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

4.  Intravenous lidocaine inhibits visceral nociceptive reflexes and spinal neurons in the rat.

Authors:  T J Ness
Journal:  Anesthesiology       Date:  2000-06       Impact factor: 7.892

5.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

6.  Intracellular pathways linking hypoxia to activation of c-fos and AP-1.

Authors:  D R Premkumar; G Adhikary; J L Overholt; M S Simonson; N S Cherniack; N R Prabhakar
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

Review 7.  Using c-fos as a neural marker of pain.

Authors:  J A Harris
Journal:  Brain Res Bull       Date:  1998       Impact factor: 4.077

8.  Measurement of myeloperoxidase in leukocyte-containing tissues.

Authors:  Y Xia; J L Zweier
Journal:  Anal Biochem       Date:  1997-02-01       Impact factor: 3.365

Review 9.  Hypersensitivity in functional gastrointestinal disorders.

Authors:  F Azpiroz
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist.

Authors:  M Miura; D C Lawson; E M Clary; A W Mangel; T N Pappas
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

View more
  4 in total

Review 1.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

Review 2.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 3.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

Review 4.  Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options.

Authors:  Emily V Wechsler; Eric D Shah
Journal:  Drugs       Date:  2021-11-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.